(Q45873712)

17 December 2017

title

Product choice and haemophilia treatment in the Netherlands (English)

1 reference

17 December 2017

0 references

0 references

Mauser-Bunschoten EP

1

1 reference

17 December 2017

Roosendaal G

series ordinal

2

1 reference

17 December 2017

van den Berg HM

series ordinal

3

1 reference

17 December 2017

publication date

1 January 2001

1 reference

17 December 2017

number of pages

3

1 reference

based on heuristic

inferred from page(s)

published in

Haemophilia

1 reference

17 December 2017

volume

7

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

96-98

1 reference

17 December 2017

Hepatitis A virus infections associated with clotting factor concentrate in the United States

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00464.X

Parvovirus B19 infection in patients with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00464.X

Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00464.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00464.X

Creutzfeldt-Jakob disease and the risk from blood or blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00464.X

10.1046/J.1365-2516.2001.00464.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017